Reuters logo
in 7 months
BRIEF-Nivalis Therapeutics announces review of strategic alternatives
January 3, 2017 / 11:14 PM / in 7 months

BRIEF-Nivalis Therapeutics announces review of strategic alternatives

2 Min Read

Jan 3 (Reuters) - Nivalis Therapeutics Inc

* Nivalis Therapeutics announces review of strategic alternatives

* Nivalis Therapeutics Inc - board of directors has initiated a process to explore and review a range of strategic alternatives

* Nivalis Therapeutics Inc - board has established a special committee to explore and evaluate strategic alternatives

* Nivalis Therapeutics Inc - company also intends to streamline its operations in order to preserve its capital and cash resources

* Nivalis Therapeutics Inc says has engaged Ladenburg Thalmann & Co. Inc. To act as its strategic financial advisor for review process

* Nivalis Therapeutics - intends to complete its ongoing SNO-7 trial of cavosonstat in patients with cf who are currently taking kalydeco (ivacaftor)

* Nivalis Therapeutics - to explore and review a range of strategic alternatives to maximize stockholder value from clinical assets and cash resources

* Nivalis Therapeutics - potential strategic alternatives that may be explored include acquisition, merger, business combination other strategic deals

* Nivalis Therapeutics Inc - ongoing SNO-7 trial of cavosonstat in patients with cf is expected to be completed in Q1 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below